ArticleEuropean journal of case reports in internal medicine2025
A Patient with Vexas Syndrome Presenting with Complete Ophthalmoplegia.
Article in European journal of case reports in internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a recently identified, somatic mutation-driven, autoinflammatory syndrome primarily affecting older males. In VEXAS, somatic Case description: We present a case of a 69-year-old male with no notable medical history who initially presented with episcleritis progressing to complete ophthalmoplegia. CT findings showed marked proptosis of the left eye and thickening of the lateral rectus. Over the subsequent months he presented to hospital repeatedly with worsening fibrotic lung disease. Eventually, after developing pancytopenia, a bone marrow biopsy showed histological features of VEXAS and the diagnosis was confirmed through genetic testing. Discussion: This case reveals a novel presentation of VEXAS and demonstrates the rapid progression to multi-organ disease possible in VEXAS. In this case, diagnostic auto-antibody panels all tested negative, and the patient was initially treated with high-dose steroids for suspected ANCA-negative vasculitis. Multiple unsuccessful attempts were made to wean and replace steroids with disease-modifying antirheumatic drugs. Following genetic confirmation of VEXAS, tocilizumab therapy was initiated. Conclusion: Due to the rapidly progressive nature of VEXAS and associated high mortality, early diagnosis is critical. This case highlights the importance of considering a bone marrow biopsy for suspicion of VEXAS when presented with an autoantibody-negative, multi-organ, autoinflammatory syndrome. LEARNING POINTS: VEXAS syndrome can initially present with ocular symptoms without systemic manifestations.VEXAS syndrome should be considered in the context of a rapidly progressive multi-organ autoinflammatory syndrome.VEXAS syndrome should be considered in the context of disease-modifying antirheumatic drug resistant inflammatory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.